GENB insider trading
NasdaqGS HealthcareGenerate Biomedicines, Inc.: insider trade history from SEC Form 4 filings.
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Company website: generatebiomedicines.com
GENB insider activity at a glance
FilingIQ tracks 25 insider transactions for GENB in filings since Mar 2, 2026. The most recent transaction is dated Sep 1, 2026.
Across the full history, 12 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GENB insider trades is 65.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GENB Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding GENB
Frequently asked
- How many insider trades does FilingIQ track for GENB?
- FilingIQ tracks 25 Form 4 insider transactions for GENB (Generate Biomedicines, Inc.), covering filings from Mar 2, 2026 onwards. 1 of those are dated within the last 90 days.
- Are GENB insiders net buyers or net sellers?
- Across the full Form 4 history for GENB, 12 transactions (48%) were open-market purchases and 1 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GENB insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is GENB in?
- Generate Biomedicines, Inc. (GENB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.54B.
Methodology & sources
Every GENB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.